Advances in the Pharmacological Treatment of Heart Failure With Preserved Ejection Fraction - PubMed
5 days ago
- #Heart Failure
- #Pharmacological Treatment
- #HFpEF
- HFpEF accounts for about half of all heart failure cases and is a growing global health issue.
- Recent advances highlight the role of systemic inflammation, endothelial dysfunction, and metabolic derangements in HFpEF.
- Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have shown consistent benefits in reducing mortality/morbidity in HFpEF.
- Finerenone, a non-steroidal mineralocorticoid receptor antagonist, has also demonstrated benefits in HFpEF treatment.
- GLP-1 receptor agonists and tirzepatide improve outcomes in obese-HFpEF patients by reducing weight and enhancing quality of life.
- HFpEF remains underdiagnosed, with diagnostic delays often hindering timely therapy.
- Comprehensive management of comorbidities and guideline-directed therapy are crucial for improving HFpEF outcomes.